Global Psychiatric Drugs Market Outlook, 2031

The global psychiatric drugs industry covers medicines used to treat mental health conditions, including major depressive disorder, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, post-traumatic stress disorder, obsessive-compulsive disorder, insomnia, postpartum depression, substance use disorders and the behavioural symptoms of dementia. Drug classes include selective serotonin reuptake inhibitors and other antidepressants, antipsychotics, mood stabilisers, anxiolytics, stimulant and non-stimulant ADHD medicines, sedatives and hypnotics, and newer classes such as NMDA receptor modulators, neurosteroids and muscarinic receptor agonists. Most prescriptions are for low-cost generics, such as sertraline, escitalopram, fluoxetine, quetiapine, aripiprazole, lithium and methylphenidate, but a significant branded market exists. Leading companies include Johnson & Johnson, with Spravato, Invega long-acting injectables and Caplyta following its 2025 acquisition of Intra-Cellular Therapies; Otsuka and Lundbeck, with Rexulti and Abilify Maintena; AbbVie, with Vraylar; Bristol Myers Squibb, with Cobenfy after its acquisition of Karuna; Takeda, with Vyvanse and Trintellix; Biogen and Sage, with Zurzuvae; Axsome, with Auvelity; Teva, Alkermes and Neurocrine. Psychedelic drug developers, such as Compass Pathways, MindMed and Cybin, and many biotechnology companies are pursuing new approaches. Mental health conditions affect nearly a billion people worldwide, making psychiatry one of the largest areas of medical need.

The pandemic led to a sharp rise in anxiety and depression and in prescriptions for antidepressants and ADHD medications, and the expansion of telehealth made it easier to obtain psychiatric care and prescriptions. Demand for ADHD stimulants grew so quickly that shortages of Adderall and other stimulants persisted in the United States from 2022 into 2024. Innovation has returned to psychiatry after decades of incremental drugs. The FDA approved Zurzuvae, the first oral treatment for postpartum depression, in August 2023, and Bristol Myers Squibb's Cobenfy in September 2024, the first schizophrenia drug with a new mechanism in decades, targeting muscarinic receptors rather than dopamine. Johnson & Johnson's Spravato nasal spray became approved as a standalone treatment for treatment-resistant depression in January 2025, and Caplyta was approved as an add-on treatment for major depressive disorder in November 2025. The path has also been uneven. AbbVie's muscarinic drug emraclidine failed in phase 2 trials in November 2024, Cobenfy's ARISE trial as an add-on therapy failed in April 2025, and the FDA declined to approve Lykos Therapeutics' MDMA-assisted therapy for PTSD in August 2024. Psychedelic research continues, with Compass Pathways reporting positive phase 3 results for psilocybin in treatment-resistant depression in 2025 and Australia allowing psychiatrists to prescribe psilocybin and MDMA since 2023. Psychedelic medicine moved much closer to approval in 2026. Compass Pathways reported positive results from a second phase 3 trial of its synthetic psilocybin COMP360 in treatment-resistant depression in February 2026, and on 18 April 2026 the US President signed an executive order directing agencies to accelerate research and review of psychedelic treatments. Six days later, the FDA awarded Commissioner's National Priority Vouchers, which can shorten review to one to two months, to Compass, the Usona Institute for psilocybin in major depressive disorder and Transcend Therapeutics for the MDMA-like compound methylone in PTSD. The FDA finalised its guidance on clinical trials of psychedelic drugs in July 2026, and Compass expects to complete its rolling submission in the fourth quarter of 2026, with a potential launch in 2027 subject to approval and rescheduling by the Drug Enforcement Administration.

Market Dynamics Market Drivers • High and Rising Prevalence of Mental Health DisordersDepression and anxiety are among the leading causes of disability worldwide, and the WHO estimates that almost a billion people live with a mental disorder. The pandemic increased rates of depression and anxiety, particularly among young people, and awareness and diagnosis of ADHD in adults has risen strongly. Reduced stigma, workplace mental health programmes and public campaigns encourage more people to seek treatment, increasing demand for psychiatric medicines.
• New Mechanisms and Faster-Acting TreatmentsAfter decades in which most new psychiatric drugs worked in similar ways, new mechanisms have reached patients, including muscarinic agonists for schizophrenia, NMDA receptor modulators such as esketamine and dextromethorphan-bupropion for depression, and neurosteroids for postpartum depression. Some of these treatments work faster than traditional antidepressants, which can take weeks. Psychedelic compounds, long-acting injectables and digital therapeutics add further options, attracting investment and increasing the value of the market.

Market Challenges • High Clinical Trial Failure RatesPsychiatric drug trials often fail because of high placebo response, subjective endpoints, heterogeneous patient populations and limited understanding of disease biology. Recent failures, including emraclidine in schizophrenia and Cobenfy's adjunctive trial, show the risks even for promising mechanisms. Regulatory standards for novel approaches, such as psychedelic-assisted therapy, are uncertain, as shown by the FDA's rejection of MDMA-assisted therapy for PTSD in 2024.
• Side Effects, Adherence and Access to CareMany psychiatric drugs cause side effects such as weight gain, metabolic problems, sexual dysfunction, sedation and movement disorders, leading many patients to stop treatment. Poor adherence is common, particularly in schizophrenia and bipolar disorder. Shortages of psychiatrists and mental health professionals, especially in low- and middle-income countries and rural areas, limit diagnosis and treatment, and stimulant medicines face strict controls and supply constraints.

Market Trends • Long-Acting Injectables and Improved AdherenceLong-acting injectable antipsychotics, given monthly, every two months, every three months or twice a year, such as Invega Hafyera, Abilify Asimtufii and Uzedy, help patients with schizophrenia and bipolar disorder maintain treatment and reduce relapse. Their use is growing as guidelines recommend earlier use. Developers are also working on long-acting formulations for other conditions, including opioid use disorder, and on digital tools that monitor adherence.
• Psychedelics and Rapid-Acting TherapiesPsilocybin, methylone, MDMA-related compounds, LSD-based drugs and DMT are in late-stage development for depression, PTSD and anxiety, and in 2026 the FDA awarded priority review vouchers to three psychedelic programmes and finalised guidance on psychedelic trials, following a US executive order to accelerate their development. These therapies are usually given with psychological support in supervised settings, requiring new care models, and approval would also require DEA rescheduling.



Segment Analysis Antidepressants and antipsychotics account for the largest share of psychiatric drug prescriptions and value, while ADHD drugs and novel mechanisms are among the fastest-growing segments. Antidepressants, including SSRIs such as sertraline, escitalopram and fluoxetine, SNRIs such as venlafaxine and duloxetine, atypical antidepressants such as bupropion, mirtazapine and vortioxetine, and newer agents such as esketamine, dextromethorphan-bupropion, zuranolone and gepirone, are among the most widely prescribed medicines in the world, used for depression and anxiety. Antipsychotics, including second-generation drugs such as aripiprazole, risperidone, paliperidone, quetiapine, olanzapine, cariprazine, lurasidone, brexpiprazole and lumateperone, treat schizophrenia, bipolar disorder and as add-ons in depression, and long-acting injectable forms command higher prices. The muscarinic agonist xanomeline-trospium represents a new class for schizophrenia. ADHD medicines, including stimulants such as methylphenidate, amphetamine salts and lisdexamfetamine and non-stimulants such as atomoxetine, viloxazine and guanfacine, have grown rapidly with rising adult diagnoses. Mood stabilisers, including lithium, valproate and lamotrigine, treat bipolar disorder. Anxiolytics, including benzodiazepines and buspirone, treat anxiety, although benzodiazepine use is increasingly restricted. Sedatives and hypnotics, including zolpidem and orexin receptor antagonists such as daridorexant, suvorexant and lemborexant, treat insomnia. Drugs for substance use disorders, including buprenorphine, naltrexone and methadone, form a growing segment. Psychedelic compounds represent a potential new segment.

Depression and anxiety disorders represent the largest indications by number of patients, while schizophrenia and bipolar disorder generate high value per patient and ADHD is one of the fastest-growing indications. Major depressive disorder affects more than 280 million people worldwide and is treated mainly with generic antidepressants, although treatment-resistant depression, postpartum depression and depression with insomnia or anxiety are growing branded segments. Anxiety disorders, including generalised anxiety disorder, panic disorder and social anxiety disorder, are the most common mental disorders and are treated with antidepressants, buspirone and benzodiazepines. Schizophrenia affects about 24 million people and requires long-term antipsychotic treatment, often with long-acting injectables, making it one of the highest-value psychiatric indications. Bipolar disorder is treated with mood stabilisers and antipsychotics. ADHD, once considered mainly a childhood condition, is now widely diagnosed in adults, and prescriptions have grown strongly since 2020, contributing to shortages. PTSD has few approved drugs and high unmet need. Obsessive-compulsive disorder is treated with SSRIs and clomipramine. Insomnia is common and treated with hypnotics and orexin antagonists. Substance use disorders, including opioid, alcohol and nicotine dependence, are treated with specific medicines. Agitation associated with Alzheimer's dementia gained its first approved treatment, brexpiprazole, in 2023. Eating disorders, autism-related irritability and Tourette syndrome are additional indications.

Oral formulations account for the vast majority of psychiatric drug use, while long-acting injectables, nasal sprays and other novel formulations are growing segments. Oral tablets, capsules and solutions are the standard route for almost all psychiatric medicines, including antidepressants, oral antipsychotics, ADHD drugs, mood stabilisers, anxiolytics and hypnotics. Extended-release formulations, such as once-daily ADHD stimulants and extended-release antidepressants, improve convenience and reduce side effects. Orally disintegrating tablets and oral films help patients who have difficulty swallowing or may hide medicines. Long-acting injectable antipsychotics, given intramuscularly or subcutaneously at intervals from two weeks to six months, are the fastest-growing high-value route, supporting adherence in schizophrenia and bipolar disorder. Long-acting injectable buprenorphine and naltrexone treat opioid and alcohol use disorders. Nasal sprays, such as esketamine, which must be given in certified clinics with monitoring, offer rapid-acting treatment for resistant depression. Intravenous brexanolone was the first postpartum depression treatment before oral zuranolone. Transdermal patches deliver methylphenidate, selegiline and some other drugs. Digital therapeutics and prescription apps are used alongside medicines in some markets. Psychedelic therapies would typically be given orally in supervised clinical sessions.

Retail pharmacies dispense the majority of psychiatric drugs, while hospital pharmacies, specialty clinics and online and telehealth channels play important and growing roles. Retail pharmacies dispense most psychiatric prescriptions, including antidepressants, oral antipsychotics, ADHD drugs and hypnotics, and they manage controlled substance regulations for stimulants and benzodiazepines. Hospital pharmacies supply medicines for psychiatric inpatient units, emergency departments and acute crises, and they administer many long-acting injectables. Community mental health centres and specialist clinics administer long-acting injectables and esketamine, which requires on-site monitoring under a risk management programme. Online pharmacies and telehealth providers have grown rapidly since 2020, particularly for depression, anxiety, ADHD and insomnia, and US telehealth flexibilities for prescribing controlled substances have been extended several times. Some telehealth companies faced scrutiny for ADHD prescribing practices. Specialty pharmacies handle high-cost psychiatric drugs, such as novel antipsychotics and treatments with special distribution requirements. Government and public mental health services purchase medicines for public hospitals, prisons and community programmes, and many countries include essential psychiatric medicines in national drug lists. Primary care physicians prescribe a large share of antidepressants and anxiolytics, while psychiatrists prescribe most antipsychotics and complex treatments.

Regional Analysis North America leads the psychiatric drugs market because of high diagnosis and treatment rates, high prices for branded medicines and early adoption of novel therapies, while Asia-Pacific is the fastest-growing region as mental health awareness and access expand. North America, led by the United States, accounts for the largest share of psychiatric drug revenue. The United States has high rates of diagnosed depression, anxiety and ADHD, extensive use of branded antipsychotics and long-acting injectables, and rapid adoption of new therapies, including Cobenfy, Spravato, Zurzuvae and Caplyta. ADHD stimulant prescriptions grew sharply after 2020, leading to shortages, and telehealth has become a major channel. Large acquisitions, including Johnson & Johnson's USD 14.6 billion purchase of Intra-Cellular Therapies completed in April 2025 and Bristol Myers Squibb's purchase of Karuna in 2024, reflect strong industry interest. Canada has similar treatment patterns with lower prices. Europe is the second largest market, with high use of generic antidepressants and antipsychotics, strict cost controls, and growing ADHD diagnosis in the UK, Germany and the Nordic countries. Some European countries are exploring psychedelic research, and the EMA has held workshops on the design of psychedelic trials. Asia-Pacific is the fastest-growing region, as mental health awareness, diagnosis and treatment expand in China, Japan, South Korea, India and Southeast Asia, although stigma and limited psychiatric workforce remain barriers. Japan has a large psychiatric drug market, and Otsuka, Takeda and Sumitomo Pharma are major developers. Australia became the first country to allow psychiatrists to prescribe psilocybin and MDMA for certain conditions from July 2023. Latin America, the Middle East and Africa have large treatment gaps, with limited access to specialists and reliance on generic medicines.

Key Developments July 2026: The FDA published final guidance for developers of psychedelic drugs, updating its 2023 draft and providing a framework for clinical trials in psychiatric conditions.
April 2026: Compass Pathways, the Usona Institute and Transcend Therapeutics received Commissioner's National Priority Vouchers for psilocybin and methylone programmes, which can shorten FDA review to one to two months.
February 2026: COMP360 met its primary endpoint in the COMP006 trial in treatment-resistant depression, following positive COMP005 results in June 2025, supporting a submission to the FDA.
November 2025: Johnson & Johnson's lumateperone was approved as an add-on treatment to antidepressants in adults with major depressive disorder.
January 2025: Johnson & Johnson's esketamine nasal spray became the first standalone treatment approved for adults with treatment-resistant depression.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Psychiatric Drugs Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Antidepressants
• Antipsychotics
• ADHD Medications
• Mood Stabilisers
• Anxiolytics
• Sedatives and Hypnotics
• Substance Use Disorder Treatments

By Indication
• Depression
• Anxiety Disorders
• Schizophrenia
• Bipolar Disorder
• ADHD
• PTSD
• Insomnia

By Route of Administration
• Oral
• Long-Acting Injectable
• Nasal
• Other

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online and Telehealth Pharmacies
• Specialty Clinics